NEW YORK (GenomeWeb) – Foundation Medicine expects to grow its clinical testing business this year while continuing to expand its pharma collaborations, following the anticipated final national coverage determination (NCD) for its FoundationOne CDx test by the Centers for Medicare and Medicaid Services later this month.
During a conference call yesterday to discuss the firm's fourth quarter earnings, CEO Troy Cox and CFO Jason Ryan provided an outline of the firm's plans and strategy for 2018.